NeuroThera Labs, in collaboration with Clearmind Medicine, has expanded its U.S. patent portfolio with three new applications covering combinations of LSD, ketamine, and ibogaine with its proprietary PEA technology. These patents aim to support treatments for mental health issues like depression and PTSD, as well as substance use and pain disorders. This builds on previous patents involving MDMA and PEA, highlighting NeuroThera's focus on innovative therapies using psychedelic compounds. The companies continue to develop safer, effective treatments for growing mental health needs while strengthening their intellectual property.
NeuroThera Labs patent expansion news provides context for health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Sep 23, 2026 18:02 WIB: Of 100 priced US health stocks, 55 rose and 37 fell. Humana Inc (HUM) closed at USD 378.73, up 1.83%, with 81% sell orders on Pluang. BridgeBio Pharma Inc (BBIO) rose 1.75% to USD 70.44, with 100% buy orders. Mesoblast Limited (MESO) fell 1.70% to USD 15.65, with a typical hold time of 12 days.
A Snap insider has sold 20,000 shares as the company's stock has declined by 27% over the last year. This insider sale may signal concerns about the stock's near-term prospects or a personal decision to liquidate holdings. Investors should watch for ...
Dogecoin (DOGE) has gained over $171 million in market cap recently, driven by a broader altcoin rally. Three AI platforms—Grok, Gemini, and ChatGPT—forecast an average price increase to $0.1082 by October 1, 2026, suggesting an 8.82% rise from curre...
Analyst Ali Martinez identifies a bullish reversal for the altcoin SUI following an 83% drop from previous highs. Three key weekly indicators—the Tom DeMark Sequential, SuperTrend, and Parabolic SAR—have flipped to buy signals, confirming a potential...
Micron's stock has risen 18.17% this week, closing at $1,096.16, with Wall Street analysts divided on price targets ranging from hold to $2,000 ahead of its September 30 earnings report. The company expects $50 billion in revenue and $31.00 non-GAAP ...
Bio-Techne shareholders have voted to approve the acquisition agreement with Merck KGaA, marking a key step toward completing the merger. The deal, which combines Bio-Techne's life science tools with Merck's global capabilities, aims to enhance suppo...
